A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia
Expert Review of Clinical Pharmacology · 2023
DOI: 10.1080/17512433.2023.2274538 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Expert Review of Clinical Pharmacology, 2023. Verfasst von Jie Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Schizophrenia, Bipolar Disorder, Major Depressive Disorder, Antipsychotic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Depression
Abstract (Originalsprache)
INTRODUCTION: The challenges posed by treatment-resistant schizophrenia and depressive symptoms have led to ongoing difficulties despite the availability of antipsychotics and antidepressants. This review addresses the potential of amisulpride analogs, particularly SEP-4199, in addressing these challenges through enhanced efficacy and reduced side effects. AREAS COVERED: This review focuses on the pharmacological profile of amisulpride analogs, exemplified by LB-102 and its derivative SEP-4199. PubMed gathered articles (up to 10 March 2023) on 'amisulpride,' 'schizophrenia,' 'bipolar disorder,' and 'major depressive disorder;' ClinicalTrials.gov tracked SEP-4199 and LB-102 trials. LB-102, a newly identified N-methylated analog of amisulpride, exhibits enhanced lipophilicity at lower doses, as demonstrated in a phase 1 study, indicating significant promise for therapeutic applications. The discovery of SEP-4199, a non-racemic analog composed of R- and S-enantiomers in an 85:15 ratio, is discussed, emphasizing its potential to enhance antidepressant effects while minimizing extrapyramidal side effects via selective D2 receptor binding. Recent phase 2 trials have demonstrated SEP-4199's efficacy in treating depressive symptoms in bipolar disorder I, capitalizing on D2-mediated anti-anhedonic and D3-mediated reward effects. EXPERT OPINION: The development of SEP-4199 presents a potential breakthrough for managing depressive symptoms in bipolar disorder I. Further exploration of D2 and D3 receptor-mediated effects could lead to improved treatment strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.
- Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
- Brain and Cognition Discovery Foundation, Toronto, ON, Canada.
- Department of Psychiatry, Yale School of Medicine, New Haven, CT, USA.
- VA New England Mental Illness, Research, Education and Clinical Center (MIRECC), VA Connecticut Healthcare System, West Haven, CT, USA.
- Department of Public Health Sciences, University of Connecticut School of Medicine, Farmington, CT, USA.
Zitieren
APA
Wu, J., Kwan, A. T., Rhee, T. G., Ho, R., d'Andrea, G., Martinotti, G., Teopiz, K. M., Ceban, F., & McIntyre, R. S. (2023). A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia. Expert Review of Clinical Pharmacology. https://doi.org/10.1080/17512433.2023.2274538
Vancouver
Wu J, Kwan AT, Rhee TG, Ho R, d'Andrea G, Martinotti G, et al. A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia. Expert Review of Clinical Pharmacology. 2023. doi:10.1080/17512433.2023.2274538
BibTeX
@article{Wu2023,
author = {Wu, Jie and Kwan, Angela Th and Rhee, Taeho Greg and Ho, Roger and d'Andrea, Giacomo and Martinotti, Giovanni and Teopiz, Kayla M and Ceban, Felicia and McIntyre, Roger S},
title = {A narrative review of non-racemic amisulpride (SEP-4199) for treatment of depressive symptoms in bipolar disorder and LB-102 for treatment of schizophrenia},
journal = {Expert Review of Clinical Pharmacology},
year = {2023},
doi = {10.1080/17512433.2023.2274538}
}
EUVIMED